

**REMARKS**

The Examiner has required restriction to one of the following inventions under 35 USC §121:

Group A: Claims 1-11 and 52-62, drawn to an immunogenic composition comprising a cholera holotoxin (CT) and an antigen wherein the CT comprises a subunit with a mutation, not an aspartic acid, and a method of immunizing the host.

Group B: Claims 12-34 and 63-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT, and a method of immunizing the host.

Group C: Claims 12-34 and 63-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT, and a method of immunizing the host.

Group D: Claims 12-34 and 63-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT, and a method of immunizing the host.

Group E: Claims 12-34 and 63-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT, and a method of immunizing the host.

Group F: Claims 12-18, 29-34, 63-69 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at Glu-29 of CT, and a method of immunizing the host.

Group G: Claims 12-16, 19, 21, 29-34, 63-67, 70, 72 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at Ile-16 and Ser-68 of CT, and a method of immunizing the host.

Group H: Claims 12-16, 20, 22, 34 and 63-67, 71, 73 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at Ser-68 and Val-72 of CT, and a method of immunizing the host.

Group I: Claims 12-15, 23, 29-34, 63-66, 74 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at amino acid 49 of CT, and a method of immunizing the host.

Group J: Claims 12-15, 23, 29-34, 63-66, 74 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at amino acids 36 and 37 of CT, and a method of immunizing the host.

Group K: Claims 12-15, 25, 28-34, 63-66, 76 and 79-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is at amino acid 30 of CT and an insertion at amino acid positions 31 and 32, and a method of immunizing the host.

Group L: Claims 12-15, 26, 29-34, 63-66, 77 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein a mutation is an insertion at 49 between amino acids 48 and 49 of CT, and a method of immunizing the host.

Group M: Claims 12-15, 27, 29-34, 63-66, 78 and 80-85 are drawn to an immunogenic composition comprising CT and an antigen covalently associated with the CT wherein the glycine and praline are inserted in the amino acids positions 36 between the wild-type positions 35 and a method of immunizing the host.

Group N: Claims 35-43 and 86-94 are drawn to an immunogenic composition comprising an E.Coli heat labile (LT) and an antigen covalently associated with LT and a method of immunizing the host.

Group O: Claims 44-51 and 95-101 are drawn to an immunogenic composition comprising a pertussis toxin (PT) and an antigen covalently associated with the PT and a method of immunizing the host.

Responsive the Requirement for Restriction, Applicants elect to prosecute the invention of Group A, claims 1-11 and 52-62, drawn to an immunogenic composition comprising a cholera holotoxin (CT) and an antigen wherein the CT comprises a subunit with a mutation, not an aspartic acid, and a method of

immunizing the host, without traverse. Applicant reserves the right to file a continuing application directed to the non-elected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,



Michael J. Moran  
Agent for Applicants  
Reg. No. 42,013

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (973) 660-7639